Bibliometric and visualized analysis of drug resistance in ovarian cancer from 2013 to 2022

Liu, Jiahua; Ma, Jingjiao; Zhang, Jiarong; Li, Chengming; Yu, Bowen; Choe, Hyok; Ding, Kaiyue; Zhang, Liu; Zhang, Lin

doi:10.3389/fonc.2023.1173863

Cited by 8 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although most ovarian cancer patients are relatively sensitive to platinum-based chemotherapy in the early stages, more than 60% of patients experience recurrence [ 4 ]. Furthermore, many patients develop secondary drug resistance after chemotherapy, which directly leads to the inability of chemotherapy drugs to effectively inhibit ovarian cancer cells, resulting in disease progression and seriously affecting the survival and quality of life of ovarian cancer patients [ 5 – 9 ]. Therefore, ovarian cancer drug resistance has become a difficult problem in clinical treatment, and the study of its mechanisms is particularly important, as these studies will provide new ideas for reversing ovarian cancer drug resistance.…”

Section: Introductionmentioning

confidence: 99%

CRABP2 affects chemotherapy resistance of ovarian cancer by regulating the expression of HIF1α

Fu,

Zhang,

Wang

et al. 2024

Cell Death Dis

View full text Add to dashboard Cite

Ovarian cancer is the most lethal malignancy among gynecologic cancers, and primary and secondary chemotherapy resistance is one of the important reasons for poor prognosis of ovarian cancer patients. However, the specifics of resistance to chemotherapy in ovarian cancer remain unclear. Herein, we find that the expression level of cellular retinoic acid binding protein 2 (CRABP2) is up-regulated in drug-resistant ovarian cancer tissues and cell lines, and the expression levels of CRABP2 in epithelial ovarian cancer tissues are closely related to tumor clinical stage and patients’ prognosis, suggesting that CRABP2 plays an important role in the progression of ovarian cancer and the corresponding ability of tumor to chemotherapy. With the in-depth study, we demonstrates that CRABP2 is related to the high metabolic activity in drug-resistant cells, and all-trans retinoic acid exacerbates this activity. Further molecular mechanism exploration experiments show that CRABP2 not only up-regulates the expression level of HIF1α, but also increases the localization of HIF1α in the nucleus. In drug-resistant ovarian cancer cells, knocking down HIF1α can block the resistance of CRABP2 to chemotherapy drugs in ovarian cancer cells. Taken together, our findings suggest for the first time that CRABP2 affects chemotherapy resistance of ovarian cancer by regulating the expression of HIF1α. This study provides a possible molecular mechanism for drug resistance and a possible molecular target for clinical treatment of ovarian cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

CRABP2 affects chemotherapy resistance of ovarian cancer by regulating the expression of HIF1α

Fu,

Zhang,

Wang

et al. 2024

Cell Death Dis

View full text Add to dashboard Cite

show abstract

“…Ovarian cancer is one of the most fatal cancers in women and the most common cause of gynecological cancer-related death worldwide [1][2][3][4]. Globally, approximately 230,000 women are diagnosed with ovarian cancer annually [5].…”

Section: Introductionmentioning

confidence: 99%

“…In Japan, the number of patients and fatalities has increased annually [7]. Although extensive studies from multiple avenues have been carried out to improve current treatment strategies [2][3][4], early detection of ovarian cancer remains a concern since the symptoms are insignificant or nonspecific in the early stage and it is often not diagnosed until stage III or IV [8]. The development of a better diagnostic test for early ovarian cancer is expected to reduce the number of fatalities from this disease.…”

Section: Introductionmentioning

confidence: 99%

Revised Cut-Off Value of Human Epididymis Protein 4 Enhances Its Use as an Ovarian Tumor Marker

Machida,

Hirakawa,

Tsunekawa

et al. 2023

Gynecol Obstet Invest

View full text Add to dashboard Cite

Objectives: Human epididymis protein 4 (HE4), a protein secreted by ovarian tumors, has been used as an ovarian tumor marker. This study aimed to improve the usefulness of HE4 to detect malignant ovarian tumors by reviewing the cut-off values. Design: Retrospective study without intervention Participants: One hundred forty nine healthy women (premenopausal, 126; postmenopausal, 23) and 24 patients with ovarian tumors (malignant, 12; benign, 12). Setting: The Department of Obstetrics and Gynecology of a University hospital in Japan and the University hospital as a workplace from 2016 to 2018. Methods: The basic performance of HE4 assay was evaluated and the serum HE4 levels of participants were measured. Receiver operating characteristic analysis was performed using the HE4 data of the patients. Results: There were no significant differences in the HE4 levels between the pre- and postmenopausal groups of healthy women. When the global cut-off values (premenopausal, 70 pmol/L; postmenopausal, 140 pmol/L) were adopted, the clinical sensitivity, specificity, positive predictive value, and negative predictive value were 41.7%, 91.7%, 83.3%, and 61.1%, respectively. Based on the results of the receiver operating characteristic analysis, we set the HE4 cut-off level at 60 pmol/L, regardless of the menopausal status. With the newly set cut-off value, the clinical sensitivity, specificity, positive predictive value, and negative predictive value were 66.7%, 91.7%, 88.9%, and 73.3%, respectively. That is, the clinical sensitivity of HE4 was improved without lowering specificity. Limitations: The small number of subjects and the fact that the health status of the healthy women was evaluated based on questionnaires were limitations to the study. Conclusion: A clinically useful cut-off value for HE4 as an ovarian tumor marker was established regardless of the menopausal status of the women, with improved clinical sensitivity, positive predictive value, and negative predictive value without lowering specificity. Currently, different cut-off values for HE4 in pre- and postmenopausal women are used globally. The cut-off value for CA125 was the same between pre- and postmenopausal women. Therefore, with the newly established cut-off value, HE4 can be used more conveniently, in a non-specialized setting, especially when it is used in combination with CA125.

show abstract

“…Baghban’s findings indicated an increasing trend in the research of extracellular vesicles and epithelial ovarian cancer ( 14 ). Conducting bibliometric analysis of literature pertaining to OC from various perspectives can aid in identifying research priorities within this domain while also presenting academic researchers with opportunities for collaboration ( 16 , 17 ). However, the current research status, development trends, and future research directions of OC imaging are still unclear.…”

Section: Introductionmentioning

confidence: 99%

Application of medical imaging in ovarian cancer: a bibliometric analysis from 2000 to 2022

Leng,

Li,

Zhu

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundOvarian cancer (OC) is the most lethal tumor within the female reproductive system. Medical imaging plays a significant role in diagnosis and monitoring OC. This study aims to use bibliometric analysis to explore the current research hotspots and collaborative networks in the application of medical imaging in OC from 2000 to 2022.MethodsA systematica search for medical imaging in OC was conducted on the Web of Science Core Collection on August 9, 2023. All reviews and articles published from January 2000 to December 2022 were downloaded, and an analysis of countries, institutions, journals, keywords, and collaborative networks was perfomed using CiteSpace and VOSviewer.ResultsA total of 5,958 publications were obtained, demonstrating a clear upward trend in annual publications over the study peroid. The USA led in productivity with 1,373 publications, and Harvard University emerged as the most prominent institution with 202 publications. Timmerman D was the most prolific contributor with 100 publications, and Gynecological Oncology led in the number of publications with 296. The top three keywords were “ovarian cancer” (1,256), “ultrasound” (725), and “diagnosis” (712). In addition, “pelvic masses” had the highest burst strength (25.5), followed by “magnetic resonance imaging (MRI)” (21.47). Recent emergent keywords such as “apoptosis”, “nanoparticles”, “features”, “accuracy”, and “human epididymal protein 4 (HE 4)” reflect research trends in this field and may become research hotspots in the future.ConclusionThis study provides a comprehensive summary of the key contributions of OC imaging to field’s development over the past 23 years. Presently, primary areas of OC imaging research include MRI, targeted therapy of OC, novel biomarker (HE 4), and artificial intelligence. These areas are expected to influence future research endeavors in this field.

show abstract

Bibliometric and visualized analysis of drug resistance in ovarian cancer from 2013 to 2022

Cited by 8 publications

References 43 publications

CRABP2 affects chemotherapy resistance of ovarian cancer by regulating the expression of HIF1α

CRABP2 affects chemotherapy resistance of ovarian cancer by regulating the expression of HIF1α

Revised Cut-Off Value of Human Epididymis Protein 4 Enhances Its Use as an Ovarian Tumor Marker

Application of medical imaging in ovarian cancer: a bibliometric analysis from 2000 to 2022

Contact Info

Product

Resources

About